Article

ISTA submits sNDA for once-daily bromfenac

ISTA Pharmaceuticals Inc. has submitted a supplemental new drug application to the FDA for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

Irvine, CA

-ISTA Pharmaceuticals Inc. has submitted a supplemental new drug application (sNDA) to the FDA for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

The company markets a 0.09% bromfenac eye drop (Xibrom) for twice-daily use beginning 24 hours after cataract surgery. If the new dosing is approved, ISTA plans to market the once-daily topical non-steroidal anti-inflammatory compound under a different brand name (XiDay).

The company expects the review to be completed in about 6 months.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.